Latest Recruitment News

Hiremii Group has raised $1.764 million through a strategic placement to fuel growth of its AI-driven recruitment platform and appointed Vaughan Webber as its new Chair.

Larvotto Resources is on track to restart production at its Hillgrove Antimony-Gold Project by mid-2026, while progressing metallurgical testing at Eyre and due diligence on a copper acquisition at Mt Isa.

Epiminder Limited has achieved a major milestone with the first US implant of its Minder System at the University of Pennsylvania, kicking off a pivotal trial that could redefine epilepsy monitoring.

Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.

Cyprium Metals has secured $80 million in funding and advanced key infrastructure works to restart copper production at its Nifty Copper Complex, targeting first cathode output by mid-2026.

Clarity Pharmaceuticals confirms continuation of its SECuRE Phase II trial for Cu-SAR-bisPSMA without protocol changes, reporting encouraging safety and efficacy data in metastatic prostate cancer patients.

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.

Estrella Resources appoints Robert Mencel as CEO, transitioning to Managing Director by mid-2026, to spearhead its limestone and manganese projects in Timor-Leste. The leadership reshuffle aims to accelerate development and operational ramp-up.

Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.

Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.